Zantac 75 launches planned by Warner-Lambert for Canada, Australia, European countries.
This article was originally published in The Tan Sheet
Executive Summary
ZANTAC 75 "ON TRACK" FOR CANADIAN LAUNCH, Warner-Lambert Chairman and CEO Melvin Goodes told securities analysts in New York City April 17. The launch would make Zantac 75 the second nonprescription H2 blocker in Canada; J&J/Merck introduced Pepcid AC there early last summer ("The Tan Sheet" July 1, 1996, In Brief). Warner-Lambert appears undaunted by J&J/Merck's significant jump on the market in Canada. SmithKline Beecham, however, recently terminated Canadian switch efforts for Tagamet HB, citing the "competitive disadvantage" that would result from trailing so far behind Pepcid AC ("The Tan Sheet" Jan. 27, In Brief).